Clinical Trials
106 trialsTesting the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
MK-3475-01G
Merck Sharp & Dohme LLC
MK-3475-01E
Merck Sharp & Dohme LLC
NeoCOAST-2
AstraZeneca
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Fox Chase Cancer Center
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
Boehringer Ingelheim
NIVIPI-Brain
Fundación GECP
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
M.D. Anderson Cancer Center
HARMONIC
Lantern Pharma Inc.
ARC-10
Arcus Biosciences, Inc.
ATATcH Alternating Treatment Plans for Advanced Cancer
Rutgers, The State University of New Jersey
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NIBCUN
Sun Yat-sen University
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
Weill Medical College of Cornell University
VELOCITY-Lung
Gilead Sciences
NEOLA
AstraZeneca
Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy
M.D. Anderson Cancer Center
Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
Massachusetts General Hospital
Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)
Big Ten Cancer Research Consortium
Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
Mayo Clinic
Pembro+Chemo in Brain Mets
University of Kentucky
Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery
Memorial Sloan Kettering Cancer Center
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
BeiGene
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
Masonic Cancer Center, University of Minnesota
NEOpredict-EGF
University Hospital, Essen
Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
ImmunoGenesis
A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
Fundación GECP
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer
Hoosier Cancer Research Network
APPEAL
Sun Yat-sen University
Afatinib With CT and RT for EGFR-Mutant NSCLC
Massachusetts General Hospital
Peri-E
Shanghai Chest Hospital
Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer
BeiGene
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
SWOG Cancer Research Network
Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer
SWOG Cancer Research Network
NSCLC
SCRI Development Innovations, LLC
Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy
University of Washington
Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901
National Hospital Organization Nagoya Medical Center
Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
Hoosier Cancer Research Network
First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC
SCRI Development Innovations, LLC
Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer
University of California, San Francisco
Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer
SCRI Development Innovations, LLC
Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients
Hoosier Cancer Research Network
Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer
SCRI Development Innovations, LLC
Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer
Emory University